



## ASX Release

8 June 2007

### New Director joins Avexa Board

Avexa Limited (ASX:AVX) today announced the appointment of Dr John Sime as a non-executive director of the company.

Dr Sime is currently a director of Prima BioMed Limited and an Adjunct Professor at Swinburne University in the School of Research and Graduate Studies.

Dr Sime has more than 25 years of experience with SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline Plc) working in the United Kingdom, Tokyo, Jakarta and Australia, and including nine years as managing Director of Beecham Australia and New Zealand.

A former director of Symbion Health Limited (formerly Mayne Group Limited) and former Chief Executive Officer of the Bioindustry Association (UK), Dr Sime brings to the Avexa Board a rare depth of biotechnology experience.

“We are delighted to have someone of John’s experience and reputation join the Avexa Board and his ability to contribute to the Phase III development and marketing programs for ATC will be particularly valuable,” said Avexa Chairman Dr Hugh Niall.

“Dr Sime’s overseas and large pharmaceutical company experience will be of great assistance to the company as we continue to grow the company and look to build a balanced product portfolio capable of generating sustainable revenue inflows well into the future,” added Chief Executive Officer Dr Julian Chick.

Born and educated in Melbourne, Dr Sime holds an Honours degree and Master of Science in Physical Chemistry from the University of Melbourne and obtained a Ph.D in Biochemistry from the Imperial College in London. Dr Sime joins fellow non-executive directors Dr Hugh Niall and Mr Stephen Cooper and executive director Dr Julian Chick on the Avexa Board.

#### For more information:

Dr. Julian Chick  
Chief Executive Officer  
+61 3 9208 4300

Mr Rod North  
Bourse Communications  
+ 61 (03) 9510-8309

[www.avexa.com.au](http://www.avexa.com.au)

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company’s lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV infections and has an exclusive option to licence TargetDrug’s lead CCR5 inhibitor, Nifeviroc.